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KESAN MITRAGININ DARIPADA MITRAGYNA SPECIOSA KE ATAS 
EKSPRESI mRNA BAGI COX-1 DAN COX-2 MENGGUNAKAN SEL 
MAKROFAJ RAW264.7 TERAWAT LIPOPOLISAKARIDA 
ABSTRAK 
Mitragyna speciosa Korth (Rubiaceae) merupakan tumbuhan ubatan yang 
digunakan secara tradisional untuk merawat pelbagai jenis penyakit terutamanya di 
Thailand dan Malaysia. Maklumat kajian bagi anti-inflamasi dan analgesik 
menggunakan ekstrak telah banyak didokumenkan. Dalam kajian ini, mekanisme sel 
bahan bioaktif utama mitraginin telah dikaji kesannya terhadap anti-inflamasi. Kesan 
mitraginin terhadap ekspresi mRNA dan ekspresi protein bagi COX-1 dan COX-2 
serta penghasilan prostaglandin E2 (PGE2) telah dikaji menggunakan sel makrofaj 
RAW264.7 terawat lipopolisakarida (LPS). RT-PCR Kuantitatif telah digunakan 
untuk menilai ekspresi mRNA bagi COX-1 dan COX-2. Ekspresi protein bagi COX-
1 dan COX-2 telah dinilai menggunakan analisis Western Blot dan tahap penghasilan 
PGE2 telah dinilai menggunakan Asai Parameter™ PGE2 (R&D Systems).  
Berdasarkan hasil kajian, mitraginin merencat secara signifikan ekspresi 
mRNA bagi COX-2 secara dos yang menaik dan diikuti dengan pengurangan 
penghasilan PGE2. Sebaliknya, kesan mitraginin terhadap ekspresi mRNA COX-1 
adalah tidak signifikan berbanding dengan sel-sel kawalan. Walau bagaimanapun, 
ekspresi protein COX-1 didapati bergantung kepada kepekatan mitraginin iaitu 
kepekatan yang lebih tinggi menunjukan perencatan seterusnya bagi ekspresi protein 
COX-1 terhadap sel-sel terawat dengan LPS. Kesimpulannya, kajian ini 
menunjukkan mitraginin telah menindas penghasilan PGE2 dengan merencat ekspresi 
mRNA COX-2 terhadap sel-sel makrofaj RAW264.7 terawat dengan LPS. Oleh itu, 
mitraginin didapati mungkin berguna dalam merawat inflamasi. 
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THE EFFECTS OF MITRAGYNINE FROM MITRAGYNA SPECIOSA ON 
THE mRNA EXPRESSION OF COX-1 AND COX-2 IN 
LIPOPOLYSACCHARIDE-STIMULATED RAW264.7 MACROPHAGE 
CELLS 
ABSTRACT 
Mitragyna speciosa Korth (Rubiaceae) is one of the medicinal plants used 
traditionally to treat various types of diseases especially in Thailand and Malaysia. 
Its anti-inflammatory and analgesic properties of its crude form are well documented. 
In this study, the cellular mechanism involved in the anti-inflammatory effects of 
mitragynine, the major bioactive constituent, was investigated. The effects of 
mitragynine on the mRNA and protein expression of COX-1 and COX-2 and the 
production of prostaglandin E2 (PGE2) were investigated in LPS-treated RAW264.7 
macrophage cells. Quantitative RT-PCR was used to assess the mRNA expression of 
COX-1 and COX-2. Protein expression of COX-1 and COX-2 were assessed using 
Western blot analysis and the level of PGE2 production was quantified using 
Parameter™ PGE2 Assay (R&D Systems).  
Based on the results of the studies, mitragynine produced a significant 
inhibition on the mRNA expression of COX-2 induced by LPS, in a dose dependent 
manner and this was followed by the reduction of PGE2 production. On the other 
hand, the effects of mitragynine on COX-1 mRNA expression were found to be 
insignificant as compared to the control cells. However, the effect of mitragynine on 
COX-1 protein expression was dependent on its concentration. Higher concentrations 
of mitragynine produced a further reduction of COX-1 expression in LPS-treated 
cells. In conclusion, these findings suggested that mitragynine suppressed PGE2 
xvi 
 
production by inhibiting COX-2 expression in LPS-stimulated RAW264.7 
macrophage cells. Thus, mitragynine may be useful in the treatment of inflammatory 
conditions. 
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INTRODUCTION 
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1.1 The plant Mitragyna speciosa Korth. (Rubiaceae) 
1.1.1 Description of the plant 
Mitragyna speciosa Korth (Figure 1.1) is a native tropical herb plant 
belonging to the family Rubiaceae (Coffee family). This species of Mitragyna is 
found mainly in sub-regions of Asia, particularly in northern parts of Malaysia, 
central and southern parts of Thailand, and Indonesia (Farah Idayu et al, 2011) . In 
Malaysia, it is popularly known by the local people as “ketum” or “biak-biak” and is 
mostly found in the states of Perlis, Kedah, Perak, Kelantan, Terengganu and 
Selangor. It is also well known in Thailand as “ithang”, “thom”, “kakuam” or 
“kratom”. Globally, this plant is known as “Kratom”. The genus was named 
“Korth” after the botanist, William Korthal, who found that the stigma of its flower 
resembles a bishop’s mitre (Shellard, 1974)   . This plant can grow to a normal height 
of 4-9 meters and to a wide of 5 meters. However, certain plants can grow up to 15-
30 meters tall. The leaves are normally of dark glossy green colour and can grow 
over 18 cm long and 10 cm wide with an ovate-acuminate shape and tapered ends (Z. 
Hassan et al, 2013) . The deep yellow flowers grow in globular clusters attached to 
the leaf axils on long stalks, bearing up to 120 florets each. The seeds are winged 
(Shellard, 1974; Shellard and Lees, 1965). At present, there are two main varieties of 
this plant which can be easily distinguished from the leaves. The petiole (vein) could 
be seen as either red or white-greenish in colour and it was believed that they 
produced different strength of effects (Murple, 2006). 
 
1.1.2 Chemical constituents of the plant 
The chemical constituents of this species especially its alkaloid extract have 
been well documented years ago. Jansen and Prast (1988)  reported that mitragynine  
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Figure 1.1  Mitragyna speciosa plant. (A) Whole plant, (B) Leaves. 
 
 
 
 
 
Figure 1.2 Chemical structure of mitragynine 
 
 
 
 
 
 
(B) (A) 
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(Figure 1.2) was obtained from the young leaves as the major constituent (66.2% 
based on the crude base) together with its analogues, speciogynine (6.6%), 
speciociliatine (0.8%), and paynantheine (8.6%) (Jansen and Prast, 1988). To date, 
over 20 alkaloids have been successfully isolated and characterized from the leaves 
(Matsumoto et al, 2005; Shellard, 1974; Takayama, 2004; Takayama et al, 2000). 
Mitragynine, the major chemical constituent of interest in this study has a molecular 
formula of 9-methoxy-corynantheidine (C23H30N2O4) with molecular weight of 
398.50 (Chee et al, 2008). The alkaloids profile of Mitragyna speciosa is 
summarized in Table 1.1 (Z. Hassan et al, 2013)  
 
1.1.3 Studies on its extracts and bioactive compound mitragynine 
Many studies on its extract and bioactive compound mitragynine have been 
carried out previously. The first pharmacokinetic study of mitragynine was reported 
by (Janchawee et al, 2007) using a HPLC-UV analysis method. It was reported that 
after oral administration of 40 mg of mitragynine in rats, the peak plasma 
concentration (Cmax) was 0.63 µg/ml at time (Tmax) of 1.83 h. The elimination rate 
constant (λz) was 0.07h-1 and the clearance was 1.60 L/h. A comprehensive 
pharmacokinetic profiles of mitragynine in human and rat plasma using a solid-phase 
extraction and HPLC-UV method was carried out (Parthasarathy et al, 2010). After 
administering 1.5 mg/kg mitragynine intravenously, the Cmax was 2.3 ± 1.2 µg/mL 
after (Tmax) 1.2 ± 1.1 h. The elimination half life (t½) was 2.9 ± 2.1 h. The clearance 
(CL) was 0.29 ± 0.27 L/h/kg. After oral administration of 50 mg/kg mitragynine, the 
Cmax was 0.7 ± 0.21 µg/mL after Tmax 4.5 ± 3.6 h with t½ of 6.6 ± 1.3 h. The apparent 
total CL was 7.0 ± 3.0 L/h/kg. It was found that the bioavailability of mitragynine 
after oral administration was 3.03 ±1.47%. 
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Mitragyna speciosa leaves have been used by locals for its opium-like effect 
and cocaine-like stimulant ability as anti-fatigue, anti-pain and as tonic to increase 
endurances or performances of work under hot sunlight (Reanmongkol Wantana et 
al, 2007). Mitragynine has also been reported to exhibit antinociceptive as well as 
analgesic properties. It was demonstrated that mitragynine has antinociceptive 
actions by suppressing mechanical and thermal noxious stimulations of supraspinal 
opioid receptors (Matsumoto et al, 1996). Later, mu-and kappa-opioid receptor 
subtypes were found to mediate these actions centrally (Thongpradichote et al, 
1998). Mitragynine was found to inhibit guinea pig ileum contraction in vitro via the 
opioid receptors (Watanabe et al, 1997). It was reported that it also inhibited the vas 
deferens contraction elicited by nerve stimulation, probably through its blockage of 
neuronal Ca2+ channels (Matsumoto et al, 2005).  
There were also several toxicity studies on the alkaloid and methanol extracts 
using animal models. It was reported that 200 mg/kg of total alkaloid extract in rats 
can be lethal (Azizi et al, 2010). Later, an acute oral toxicity study at three different 
doses (100, 500 and 1000 mg/kg) of standardized methanol extract was found not to 
have any effect on water and food consumption as well as spontaneous behavior in 
rats (Harizal et al, 2010). However, it was observed that there was a significant 
increase in alanine transaminase (ALT) and aspartate aminotransferase (AST) at 
these doses. Nephrotoxicity was observed at 1000 mg/kg as evidenced by elevated 
creatinine. Histological examinations showed congestion of sinusoids, haemorrhage 
hepatocytes, fatty change, centrilobular necrosic and increased number of Kuppfer 
cells in the liver (Harizal et al, 2010). It was reported that the methanolic extract of 
Mitragyna speciosa has anti-inflammatory effects in Sprague dawley rats (Raja 
Aziddin RE et al, 2005; Shaik Mossadeq et al, 2009). In a recent in vivo study, 
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mitragynine has shown to exert an antidepressant effect in animal behavioral model 
depression (FST and TST) and the effect appears to be mediated by an interaction 
with neuroendocrine HPA axis systems (Farah Idayu et al, 2011) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Table 1.1 The estimated percentage of compounds in the alkaloid extracts of 
Mitragyna speciosa Korth (Z. Hassan et al, 2013) 
Alkaloids Percentage Effects References 
Mitragynine 66% Analgesic, 
antitussive, 
antidiarrheal, 
adrenergic, 
antimalarial 
(Field, 1921; Hooper, 1907; 
Lee et al, 1967; Ponglux et 
al, 1994) 
Paynantheine 9% Smooth muscle 
relaxer 
(Ponglux et al, 1994) 
Speciogynine 7% Smooth muscle 
relaxer 
(Lee et al, 1967; Ponglux et 
al, 1994; Shellard, 1974; 
Shellard et al, 1978b) 
7-Hydroxymitragynine 2% Analgesic, 
antitussive, 
antidiarrheal 
(Ponglux et al, 1994) 
Speciociliatine 1% Weak opioid 
agonist 
(Lee et al, 1967; Ponglux et 
al, 1994) 
Mitraphylline <1% Vasodilator, 
antihypertensive, 
muscle 
relaxer, diuretic, 
antiamnesic, 
immunostimulant, 
anti-leukemic 
(Ponglux et al, 1994; Seaton 
et al, 1958; Shellard, 1974; 
Shellard et al, 1978b) 
Isomitraphylline <1% Immunostimulant, 
anti-leukemic 
(Ponglux et al, 1994; Seaton 
et al, 1960; Shellard and 
Philipson, 1966) 
Speciophylline <1% Anti-leukemic (Beckett et al, 1966; Shellard 
and Philipson, 1966) 
Rhynchophylline <1% Vasodilator, 
antihypertensive, 
calcium 
channel blocker, 
antiaggregant, 
anti-inflammatory, 
antipyretic, 
anti-arrhythmic, 
antihelminthic 
(Seaton et al, 1960; Shellard, 
1974; Shellard et al, 1978b) 
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Table 1.1 Continued 
Alkaloids Percentage Effects References 
Isorhynchophylline <1% Immunostimulant (Seaton et al, 1960; Seaton et 
al, 1958; Shellard, 1974; 
Shellard et al, 1978b) 
Ajmalicine <1% Cerebrocirculant, 
antiaggregant, 
anti-adrenergic, 
sedative, 
anticonvulsant, 
smooth muscle 
relaxer 
(Beckett et al, 1966) 
Corynantheidine <1% Opioid agonist (Takayama et al, 2002) 
Corynoxine A <1% Calcium channel 
blocker, 
anti-locomotor 
(Shellard et al, 1978a) 
Corynoxine B <1% Anti-locomotor (Shellard et al, 1978a) 
Mitrafoline <1%  (Hemmingway et al, 1975; 
Shellard et al, 1978a) 
Isomitrafoline <1%  (Hemmingway et al, 1975; 
Shellard et al, 1978a) 
Oxindale A <1%  (Shellard et al, 1978a) 
Oxindole B <1%  (Shellard et al, 1978a) 
Speciofoline <1% Analgesic, 
antitussive 
(Hemmingway et al, 1975) 
Isospeciofoline <1%  (Hemmingway et al, 1975; 
Shellard et al, 1978a) 
Ciliaphylline <1% Analgesic, 
antitussive 
(Trager et al, 1968) 
Mitraciliatine <1%  (Lee et al, 1967) 
Mitragynaline <1%  (Houghton et al, 1991) 
Mitragynalinic acid <1%  (Houghton et al, 1991) 
Corynantheidalinic acid <1%  (Houghton et al, 1991) 
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1.2 Inflammation and pain 
1.2.1 Inflammation 
The word inflammation is derived from the Latin “inflammare” (to burn). It is 
one of the most important biological responses involved in the defense of an 
organism against local injury and harmful stimuli such as pathogens or irritants. It 
often progresses to painful or chronically harmful inflammatory diseases requiring 
appropriate medicinal treatment (Laupattarakasem et al, 2003; Vane et al, 1994). 
Typical inflammatory diseases such as rheumatoid, asthma, colitis and hepatitis are 
among the leading causes of death and disability in the world (Cirino et al, 2003; 
Emery, 2006; Jiang and Ames, 2003). The development of several inflammatory 
diseases including cancer, cardiovascular and neurodegenerative disorders are due to 
chronic inflammation (Jiang and Ames, 2003; Willerson and Ridker, 2004). 
Inflammatory response is a series of well coordinated dynamic mechanism 
consisting of specific vascular, humoral and cellular events that is characterized by 
movement of fluids, plasma and inflammatory leukocytes (neutrophils, eosinophils, 
basophils and macrophages) to the site of inflammation (Gokhale et al, 2002; Hou et 
al, 2004). A variety of chemical mediators or signaling molecules such as histamines, 
serotonin, leukotrienes, prostaglandins and oxygen derived free radicals are produced 
by inflammatory and phagocytic cells predominantly in the sequences which 
participate in onset of inflammation (Safayhi and Sailer, 1997; Vijayalakshmi et al, 
1997). Inflammatory response occurs in two phases which are known as acute and 
chronic and each is apparently mediated by a different mechanism. 
 
 
 
10 
 
1.2.1.1        Acute inflammation 
Acute inflammation is the immediate defence to tissue-specific 
damage. The cardinal signs of acute inflammation are those described by Celsus in 
the 1st century AD as rubor (redness), calor (heat), tumor (swelling) and dolar (pain) 
(Nathan, 2002). These symptoms arise due to dilation of blood vessels, causing 
increased blood flow and migration of white blood cells to the affected area, and they 
terminate once the cells are properly healed. The events involved in acute 
inflammation can be divided into vascular and cellular. 
1.2.1.1.1 Vascular events 
Vascular events occur in micro vasculature and become apparent in 
15-30 minutes after tissue injury, infection and in the presence of other inflammatory 
stimuli. It is mainly mediated by chemicals such as serotonin and histamine released 
from mast cells. It is actually a transient phase and is characterized by local 
vasodilations of venules and capillaries resulting in an increased blood flow to the 
inflamed tissue, thereby giving rise to localized redness and heat followed by an 
increase in vascular permeability leading to transudation of fluids, plasma and 
vascular protein into the inflammatory sites producing interstitial oedema (Gallin et 
al, 1992; Nathan, 2002).  
 
1.2.1.1.2 Cellular events 
The infiltration of leukocytes from circulating blood is crucial in 
inflammatory reaction (Muller, 2002; Negrotto et al, 2006). A variety of chemotactic 
agents such as bacterial products possessing amino terminal N-formyl methionyl 
groups, C5a complement fragment and chemokines along with mediators of mast 
cells like histamine and leukotriene B4 (LTB4) and platelets activating factor (PAF) 
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elicit profound leukocytes infiltration within 30-60 minutes (Asako et al, 1992; Raud 
et al, 1989). The first inflammatory cells or leukocytes that are recruited at the site of 
acute inflammation are known as neutrophils (Hou et al, 2004; Miyazaki et al, 2000). 
Cell infiltration occurs through a process in which leukocytes interact with 
endothelium in post capillary venules. This process involves its sequential capture, 
rolling along and firm adhesion to the micro vascular endothelium, followed by 
transmigration through the vessel wall and further migration in extravascular tissue 
(Muller, 2002). All these steps in the recruitment cascade are controlled by cell 
adhesion molecules (CAM) such as selectin, integrins (CD11 and CD18) and 
intracellular adhesion molecules (ICAM-1 and -2). There are three members of the 
selectin family of CAMs which are expressed on both leukocytes (L-selectin) and 
endothelial cells (P-selectin and E-selectin). These molecules mediate low affinity 
adhesion of leukocytes and endothelial cells during rolling process (Vestweber and 
Blanks, 1999). High-affinity adhesion molecules of leukocytes on endothelium are 
mediated by interaction between integrins (CD11/CD18) and adhesion molecules 
(CAM-1 and CAM-2) expressed on leukocytes and endothelium cells, respectively 
(Ulbrich et al, 2003). Following a period of stationary adhesion, a leukocyte may 
leave the post capillary venules by extending pseudopodia between endothelial cells 
and reach into the subendothelial space. This complex process is often known as 
leukocytes extravasations and transendothelial migration. 
 
1.2.1.2  Chronic inflammation 
Chronic inflammation is characterized by infiltration of mononuclear 
cells such as macrophages and lymphocytes, proliferation of fibroblast, collagen 
fibers and formation of connective tissue which ultimately lead to 0.5 – 2.0 mm large 
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granuloma (tumour like swelling). In this situation tissue degeneration is mainly 
mediated by reactive oxygen and nitrogen species and proteases produced from 
infiltrated inflammatory cells (Suleyman et al, 2004). These reactive oxygen species 
are mutagenic and during the process of repeated tissue damage and regeneration, 
they interact with DNA in proliferating epithelium resulting in permanent genomic 
alterations such as point mutations, deletions or rearrangements (Maeda and Akaike, 
1998). Indeed, p53 mutations are seen in chronic inflammatory diseases such as 
rheumatoid arthritis and inflammatory bowel diseases at frequencies similar to those 
in tumours (Yamanishi et al, 2002). Thus, chronic inflammation ultimately, progress 
to carcinoma (Coussens and Werb, 2002). 
 
1.2.2 Pain 
Pain normally serves as an alarm system activated in response to impending 
damage to the organism. It is an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage as per the International Association 
for the Study of Pain (IASP) (Merskey and Bogduk, 1994). It is a multidimensional 
experience, which contains essentially a sensory, cognitive and emotional component 
(Woolf, 2004). Pain can be classified into different categories according to various 
criteria, such as those based on the cause of pain, its duration, location, underlying 
diseases etc. The most widely used criteria are aetiological (i.e. based on the cause of 
pain). In this regard, pain can be classified into three categories, nociceptive, 
inflammatory and neuropathic. Nociceptive pain is generated by activation of 
noniceptors that are specialized to be activated by noxious stimuli which have the 
potential of causing tissue damage. Nociception or nociceptive pain is essential in 
survival for organisms to avoid potential or actual tissue damage (Scholz and Woolf, 
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2002). Nociceptive pain is mostly recognized as acute pain since that pain stops 
when the stimulus has been removed. 
Inflammatory pain is associated with processes that can be caused by tissue 
damage, infections, tumor growth and various forms of chronic inflammatory 
diseases, such as autoimmune disease. During inflammation, multiple mediators are 
released locally from the damaged and recruited inflammatory cells. This results in 
the release of cytokines, growth factors, neuropeptides, kinins, purines, amines, 
prostanoids and ions, including protons (Boddeke, 2001; Mantyh et al, 2002). These 
mediators can activate and sensitize nociceptors, thus evoke pain (Scholz and Woolf, 
2002). The symptoms of inflammation include cell migration, oedema, erythema, 
pain and hyperalgesia (Marchand et al, 2005). In most cases, inflammatory pain 
responds to non-steroidal anti-inflammatory drugs (NSAIDs) or opiates such as 
morphine (Fitzcharles et al, 2010). Inflammatory pain under many conditions such as 
rheumatoid arthritis (RA) is chronic. Chronic inflammatory pain can be characterized 
by hyperalgesia (greater pain after normally painful stimuli) and allodynia (normally 
non-noxious stimuli that are perceived as painful). 
Neuropathic pain arises from a primary lesion or dysfunction in the peripheral 
or central nervous system (CNS) such as painful polyneuropathy, postherpetic 
neuralgia, trigeminal neuralgia, spinal cord injury pain and post-stroke pain.  
(Merskey and Bogduk, 1994). Clinically, neuropathic pain is characterized by 
spontaneous on-going or shooting pain and evoked pain such as hyperalgesia and 
allodynia (Baron et al, 2010). Neuropathic pain is mostly chronic, difficult to treat 
and associated with plasticity in the central and peripheral nervous system. The 
mechanisms of neuropathic pain are not well understood and treatments are largely 
unsatisfactory. Neuropathic pain may respond to some antiepileptics, tricyclic 
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antidepressant, and antiarrhythmics. Local anesthetics used to block the nerve may 
also be effective in some cases. 
 
1.3 Molecular mechanisms of inflammation and pain 
1.3.1 Cyclooxygenase (COX)  
Cyclooxygenase (COX), also known as prostaglandin-endoperoxide synthase, 
is a heme-containing enzyme involved in the metabolism of arachidonic acid (AA) 
and the synthesis of prostanoids including potent pro-inflammatory prostaglandins 
(PGE2, PGF2α) (Hood et al, 2003; Mitchell et al, 1993). In mammalian cells, COX 
exist in at least two isoforms COX-1 and COX-2 (Fu et al, 1990; Langenbach et al, 
1995; Xie et al, 1991). It is generally considered that COX-1 is constitutively 
expressed in almost all cell types, including platelets and those present in the 
stomach, kidney, vascular endothelium, forebrain and uterine epithelium and is 
regulated as a house keeping enzyme for various physiological functions. COX-2 is 
inducible and expressed during tissue damage or inflammation in response to pro-
inflammatory cytokines such as interleukin-1-beta (IL-1β), interferon gamma and 
tumor necrosis factor-alpha (TNF-α) (Akarasereenont et al, 1994; Arias-Negrete et 
al, 1995; Hood et al, 2003; Warner et al, 1999). Therefore, COX-2 has been 
implicated in pathogenesis, such as inflammation, pain, fever and cancer (Murakami 
and Kudo, 2004). 
The human cyclooxygenase genes have been cloned and assigned to different 
chromosomes, the COX-1 gene is present on chromosome 9 and the COX-2 on 
chromosome 1 (Kosaka et al, 1994; Tazawa et al, 1994). The COX-1 gene contains 
11 exons in 22 kb and COX-2 gene has 10 exons in 8.3 kb (Kraemer et al, 1992). 
Both isoforms of cyclooxygenase are structurally distinct proteins, the amino acid 
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sequence of their complementary DNA showing approximately 60% homology 
(Kurumbail et al, 1996). COX-1 contains 576 amino acids and COX-2 contains 587 
amino acids with a molecular mass of ~71 kDa. Although both the isozymes have 
similar active site for their natural substrate arachidonic acid (AA), slight differences 
between the two isozymes were evident in 3-D structural analysis. In COX-1 the 523 
position is occupied by an isoleucine, while in COX-2 the same position is occupied 
by a valine residue which is different by a single methyl group. The smaller valine 
residue in COX-2 produced a large gap in the enzyme channel, giving access to site 
pocket which is thought to be the binding site of many selective COX-2 inhibitory 
agents (Cannon et al, 1998; Lanzo et al, 1998; Marnett and Kalgutkar, 1999; Wong 
et al, 1997). 
 
1.3.2 Prostaglandins biosynthesis 
The COX isozymes are integral membrane proteins. Arachidonic acid that is 
released from the membrane adjacent to the opening of the enzyme channel, is 
attracted to its hydrophobic region and later transformed into prostaglandins and 
other related metabolites. COX- enzymes possess two distinct catalytic activities: a 
cyclooxygenase activity which catalyzes the formation of a C-5 ring molecule called 
PGG2 by reacting with two molecules of oxygen and a peroxidase activity in which 
the peroxide group at C-15 is reduced to an alcohol with the formation of PGH2 
(Funk, 2001; Pulichino et al, 2006). PGH2 is the precursor for the different 
biologically active prostaglandins and thromboxanes (Vane et al, 1998) (Figure 1.3). 
Several isomerases such as PGD synthase, PGF synthase and PGE synthase catalyze 
the transformation of PGH2 into different prostaglandin PGD2, PGF2α, PGE2 
respectively. Prostacyclin synthase catalyzes the transformation of PGH2 into 
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prostacyclin (PGI2) and thromboxane synthase carries out the transformation of 
PGH2 into thromboxanes A2. 
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Figure 1.3 The arachidonic acid cascade and prostaglandins biosynthesis  (Vane 
et al, 1998) 
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1.3.3 Physiological and pathophysiological role of prostaglandins 
Prostanoids formed by COX-1 are important in many physiological functions 
including the regulation of platelet aggregation. Thromboxane TXA2 induces platelet 
aggregation while PGI2 exhibits antiaggregatory properties. In the gastrointestinal 
tract, PGI2 and PGE2 reduce gastric acid secretion, exert a direct vasodilator action 
on the vessels of the gastric mucosa and stimulate the production of viscous mucus 
which forms a protective barrier (Vane and Botting, 1998). In the kidney, vasodilator 
prostaglandins (PGI2, PGE2 and PGD2) play a key role in regulating renal blood 
flow, diminishing vascular resistance, dilating renal vascular beds and enhancing 
organ perfusion (Whelton, 1999). COX-1 is found in neurons throughout the brain, 
but is most abundant in the forebrain where PGs may be involved in complex 
integrative functions (Breder et al, 1995; Yamagata et al, 1993). It is also expressed 
in the uterine epithelium in early pregnancy and may be important for implantation 
of the ovum and for angiogenesis necessary to establish the placenta (Chakraborty et 
al, 1996). 
On the other hand, prostaglandins (PGE2 and PGI2) are substantially involved 
in maintaining the inflammatory process by increasing vascular permeability and 
amplifying the effect of other inflammatory mediators such as kinin, serotonin and 
histamine. Thus, contributing to the redness, increased blood flow and plasma 
exudation in the area of acute inflammation which leads to oedema. These PGs 
produce hyperalgesia by sensitizing afferent C fibers. Moreover, PGE2 acts on 
neurons in the thermoregulatory network of the hypothalamus, causing increase in 
body temperature. Elevated levels of multiple PGs including PGE2 and PGI2 have 
been reported in synovial fluids from patients with rheumatoid arthritis and 
osteoarthritis (Egg, 1984; Pulichino et al, 2006). Prostaglandins also play an 
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important role in the pathogenesis of several types of cancers such as breast, liver 
and lung with over expression of COX-2 and over production of prostaglandin 
(Achiwa et al, 1999; DuBois, 2001; Hwang et al, 1998). 
Pain and inflammation are mediated by PGE2 and PGI2 through their actions 
on various receptors. PGE2 G-protein coupled receptor subtypes (EP1, EP2, EP3 and 
EP4) and PGI2 receptor (IP) have been identified (Lin et al, 2006; McCoy et al, 
2002; Pulichino et al, 2006). At the site of inflammation, PGE2 sensitizes peripheral 
pain through activation of EP receptors present on the peripheral terminals of sensory 
neurons (Lin et al, 2006). Similarly, in another study PGI2 receptor deficient mice 
display an impaired acute inflammatory response in carrageenan-induced paw 
oedema and acetic acid-induced writhing (Murata et al, 1997), indicating the 
participation of PGI2 receptor in inflammation.  
 
1.4 Therapeutic management for inflammation and pain 
1.4.1 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
Inflammation and pain are currently regularly treated by non-steroidal anti-
inflammatory drugs (NSAIDs).  NSAIDs are the most commonly used over-the-
counter drugs (A Mahajan and Rashmi Sharma, 2005). Aspirin (acetylsalicylic acid) 
is one of the NSAIDs available in the market since 1899. It was introduced by the 
chemist Felix Hoffman (Wallace, 1997). The 1960s was a key decade for the 
discovery of various classes of NSAIDs essential for the treatment of pain and 
inflammation. A significant advancement in the evaluation of NSAIDs was made by 
two important discoveries. Firstly, the substantial progress made in 1970s in 
elucidating the mechanism of action of NSAIDs related to inhibition of 
prostaglandins by cyclooxygenase pathway. Secondly, the identification of two 
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isoforms of cyclooxygenase (COX) in the 1990s (Lin et al, 2006; Vane and Botting, 
1998; Warner et al, 1999). NSAIDs can act as nonselective COX inhibitors or 
selective COX-2 inhibitors based on its selectivity towards cyclooxygenases. 
 
1.4.2 Non-selective cyclooxygenase inhibitors 
Non-selective NSAIDs belong to a heterogenous group of chemical 
substances that inhibit both constitutively expressed COX-1 and the inducible COX-
2 almost with the equal potency. Most of the NSAIDs are carboxylic acid containing 
drugs such as salicylate derivatives (e.g. aspirin), carboxylic and heterocyclic acid 
derivatives (e.g. indomethacin), fenamic acid derivatives (e.g. mefenamic acid), 
propionic acid derivatives (e.g. ibuprofen, ketoprofen, flurbiprofen and naproxen) 
and phenyl acetic acid derivatives (e.g. diclofenac). NSAIDs having enolic acid 
containing drugs include oxicam derivatives (e.g. piroxicam, tenoxicam and 
meloxicum) and pyrazoles (e.g. phenylbutazone). These organic acid containing 
drugs act at the site of the enzyme and interact with the guanidinium group of Arg-
120, thereby preventing the access of AA to the enzyme and so stop the 
cyclooxygenase pathway (Derle et al, 2006; Mancini et al, 1995). 
The classical NSAIDs (aspirin like drugs) are among the most widely 
prescribed drugs worldwide as analgesic, antipyretic and anti-inflammatory agents 
and have become an important drug in the control of inflammation and pain 
associated with musculoskeletal pathologies such as rheumatoid arthritis, 
osteoarthritis, gout tendonitis, muscle strain, postoperative and post traumatic 
inflammation, thrombophlebitis and vasculitis (Pulichino et al, 2006; Smith et al, 
1998; Steinmeyer, 2000; Warner et al, 1999).  
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1.4.3 COX-2 inhibitors 
Considering the side effects of classical NSAIDs, a selective blockade of the 
COX-2 isoform would lead to the inhibition of pain and inflammation without 
impending the COX-1 dependent affect in the GI tissue and kidney (Hawkey, 1999; 
van Ryn and Pairet, 1999). Thus in 1999, rofecoxib (Vioxx) and celecoxib 
(Celebrex) were developed as a leading anti-arthritic drug with 800 and 375 fold 
more selectivity, respectively towards COX-2, than COX-1. Clinical studies revealed 
that both drugs possess similar efficacy to diclofenac and naproxen but there was a 
lower incidence of gastrointestinal adverse effect in prolonged use (Alvaro-Gracia, 
2004; Bertolini et al, 2002; Cannon et al, 1998; van Ryn and Pairet, 1999). However, 
various clinical studies have raised concern about the cardiovascular safety in the use 
of selective COX-2 inhibitors, as long term use of these inhibitors increase the risk of 
myocardial infarction and stroke in patients with rheumatoid arthritis (Bombardier et 
al, 2000; Bresalier et al, 2005). This cardiac risk is mainly attributed to the inhibition 
of prostacyclin (PGI2) which would cause a severe physiological imbalance between 
prothrombotic thromboxane A2 (levels are raised) and vasodilatory prostacyclin 
(decline) levels in the endothelium, favoring platlet aggregation and vasoconstriction 
(Lin et al, 2006; Linton and Fazio, 2004). As a result of which in September 2004 the 
use of Vioxx was banned in the treatment of rheumatoid arthritis. 
 
1.4.4 Opioids  
Opioids is one of the treatments given to patients in managing pain. Opioids 
have an important role in acute pain management of moderate to severe pain, but the 
dangers of chronic use have long been of concern. The following information about 
the mechanism of action of opioids is excerpted from Nicholson 2003. Opioids 
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mediate their actions by binding and activating endogenous opioid receptors that 
comprise part of a pain-modulating pathway that descends from the midbrain to the 
spinal cord dorsal horn. Opioids receptors and endogenous opioid peptides have also 
been identified in the peripheral nervous system. Opioid receptors consist of three 
subtypes: mu (µ), delta (δ) and kappa (ĸ). The pharmacological effects of the opioid 
analgesics are derived from their complex interactions with these three opioid 
receptors (Inturrisi, 2002). Most opioid drugs, for which morphine is the prototype, 
are relatively selective for µ-receptors. These drugs are full agonists and through 
their stimulation of µ-receptors produce analgesia, affect mood and rewarding 
behavior, and alter respiratory, cardiovascular, gastrointestinal, and neuroendocrine 
functions. 
In recent years, this notion has been challenged or de-emphasized, and many 
clinicians who treat chronic pain have assumed that maintenance opioids retain 
analgesic efficacy despite a lack of good evidence for this assumption (Streltzer and 
Johansen, 2006). Chronic stimulation of the µ-opioid receptor results in a cascade of 
cellular responses with multiple overlapping mechanisms, which can result in 
enhanced pain sensitivity, known as hyperalgesia (Chang et al, 2007). Some of the 
cellular responses to chronic opioid intake that are thought to contribute to 
hyperalgesia include an increase in neuropeptides such as dynorphin (Vanderah et al, 
2001), cholecystokinin (Xie et al, 2005), and substance P (King et al, 2005) all of 
which have been demonstrated to enhance pain sensitivity and the activation of glial 
cells, producing inflammatory cytokines and resulting in amplified pain (Watkins et 
al, 2007).  
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1.5 Objectives of the study 
At present, the studies on anti-inflammatory and analgesic properties of 
extracts of Mitragyna speciosa are well documented; however, the cellular 
mechanisms involved in the anti-inflammatory effects of mitragynine, the major 
bioactive constituent has yet to be elucidated. Therefore, this study is important for 
our understanding on the involved cellular mechanisms specifically on the 
modulation of COX-1 and COX-2 genes and protein expression as cyclooxygenase 
(COX) enzymes play an important role in the induction of pain and inflammation as 
well as the analgesic actions of NSAIDs.  COX-1 is constitutively expressed in 
almost all cell types, including platelets and those present in the stomach, kidney, 
vascular endothelium, forebrain and uterine epithelium and is regulated as a house 
keeping enzyme for various physiological functions. COX-2 is inducible and 
expressed during tissue damage or inflammation in response to pro-inflammatory 
cytokines. The objectives of the present study are to determine: 
1. The cytotoxicity effects of mitragynine in RAW264.7 macrophage cells. 
2. The effects of mitragynine on mRNA and protein expression of COX-1 
and COX-2 in LPS-stimulated RAW264.7 macrophage cells.  
3. The effects of mitragynine on Prostaglandin E2 (PGE2) production in 
LPS-stimulated RAW264.7 macrophage cells.  
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